Literature DB >> 12771882

Nitric oxide synthase expression by pulmonary arteries: a predictive marker of Fontan procedure outcome?

Marilyne Lévy1, Claire Danel, Anne-Marie Laval, Francine Leca, Pascal R Vouhé, Dominique Israël-Biet.   

Abstract

OBJECTIVES: We retrospectively analyzed lung biopsy specimens from patients who underwent the Fontan procedure to identify predictive markers of outcome.
METHODS: We studied the intra-acinar pulmonary arteries present in lung biopsy specimens from 17 patients undergoing the Fontan procedure. We evaluated both their morphology and their expression of endothelial nitric oxide synthase and endothelin 1. We compared these data with those of 6 patients who died of no pulmonary cause (control group).
RESULTS: Eight patients had a good surgical outcome (group 1). Their distal arteries were thin and weakly expressed endothelin 1 and endothelial nitric oxide synthase. The procedure failed in 9 patients (group 2). Their distal arteries displayed muscle extension with an increased wall thickness (P <.01 vs group 1). Their endothelin 1 expression remained low (not significant vs group 1). By contrast, endothelial nitric oxide synthase was markedly overexpressed (P <.001 vs group 1).
CONCLUSION: Distal pulmonary arteries of patients in whom the Fontan procedure failed exhibited a markedly increased wall thickness and a clear endothelial nitric oxide synthase overexpression. In addition to giving clues to the pathogenesis of the procedure's failure, our study might help to define reliable predictive markers of its outcome.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12771882     DOI: 10.1067/mtc.2003.193

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  9 in total

1.  Effect of inhaled iloprost on the exercise function of Fontan patients: a demonstration of concept.

Authors:  Jonathan Rhodes; Ana Ubeda-Tikkanen; Mathieu Clair; Susan M Fernandes; Dionne A Graham; Carly E Milliren; Kevin P Daly; Mary P Mullen; Michael J Landzberg
Journal:  Int J Cardiol       Date:  2013-03-29       Impact factor: 4.164

2.  Lost unilateral capillary perfusion during nonpulsatile pulmonary circulation: successful recovery by oral sildenafil.

Authors:  Levent Celik; Konstantin Papakostas; Markus Lentschig; Victor Hraska; Jan-Hendrik Nürnberg
Journal:  Pediatr Cardiol       Date:  2011-11-27       Impact factor: 1.655

Review 3.  Medical management of the failing Fontan.

Authors:  N S Ghanayem; S Berger; J S Tweddell
Journal:  Pediatr Cardiol       Date:  2007 Nov-Dec       Impact factor: 1.655

Review 4.  Pulmonary Hypertension in Children.

Authors:  Dunbar Ivy
Journal:  Cardiol Clin       Date:  2016-08       Impact factor: 2.213

5.  Routine Sildenafil Does Not Improve Clinical Outcomes After Fontan Operation.

Authors:  J Leslie Gaddis Collins; Mark A Law; Santiago Borasino; W Clinton Erwin; David C Cleveland; Jeffrey A Alten
Journal:  Pediatr Cardiol       Date:  2017-09-07       Impact factor: 1.655

6.  Effect of Inhaled Nitric Oxide on Blood Flow Dynamics in Patients After the Fontan Procedure Using Cardiovascular Magnetic Resonance Flow Measurements.

Authors:  Heiner Latus; Bettina Gerstner; Gunter Kerst; Axel Moysich; Kerstin Gummel; Christian Apitz; Juergen Bauer; Dietmar Schranz
Journal:  Pediatr Cardiol       Date:  2015-11-07       Impact factor: 1.655

Review 7.  Orthotopic heart transplantation in patients with univentricular physiology.

Authors:  Guido Michielon; Adriano Carotti; Giacomo Pongiglione; Paola Cogo; Francesco Parisi
Journal:  Curr Cardiol Rev       Date:  2011-05

Review 8.  Diagnosis, Evaluation and Treatment of Pulmonary Arterial Hypertension in Children.

Authors:  Benjamin S Frank; D Dunbar Ivy
Journal:  Children (Basel)       Date:  2018-03-23

9.  Homoarginine-A prognostic indicator in adolescents and adults with complex congenital heart disease?

Authors:  Tanja Raedle-Hurst; Marieke Mueller; Andreas Meinitzer; Winfried Maerz; Thomas Dschietzig
Journal:  PLoS One       Date:  2017-09-08       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.